Viewing Study NCT01532466


Ignite Creation Date: 2025-12-24 @ 4:34 PM
Ignite Modification Date: 2025-12-27 @ 1:18 PM
Study NCT ID: NCT01532466
Status: COMPLETED
Last Update Posted: 2012-02-14
First Post: 2012-02-07
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: The Effect of Priming Intravenous Rocuronium on Fentanyl-Induced Coughing
Sponsor: Taichung Armed Forces General Hospital
Organization:

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2011-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: An intravenous bolus of fentanyl often induces a cough reflex. This study investigates whether priming with rocuronium can attenuate fentanyl-induced coughing effectively.
Detailed Description: Fentanyl is widely used for analgesia and anesthesia because of its rapid onset, its intense analgesic effect, and is associated with lessened cardiovascular depression and low histamine release. Although the cough reflex is usually transient and self-limiting, it should be avoided in situations such as elevated intracranial, intraocular, or intra-abdominal pressure, and unstable hemodynamics.

The cause of FIC is unclear. One hypothesis is that vocal cord spasms might induce coughing because of fentanyl-induced muscle rigidity and histamine release. Muscle relaxants are commonly used to treat this condition. This study hypothesizes that priming muscle relaxants could prevent or suppress FIC. This study investigates whether the muscle relaxant rocuronium attenuates FIC effectively.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: